(PharmaNewsWire.Com, April 29, 2025 ) InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global In vivo CAR T-cell Market Size, Share & Trends Analysis Report By Delivery Systems (Lipid Nanoparticles (LNPs), Viral Vectors, Oncolytic Viruses), Targets (Hematological Cancers, Solid Tumors, Non-Oncology) – Market Outlook And Industry Analysis 2034″
In vivo CAR T-cell Market Size is predicted to grow at a 32.9% CAGR during the forecast period for 2025-2034.
Global In vivo CAR T-cell Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2999
The in vivo CAR T-cell industry is a fast-evolving and revolutionizing field of cancer immunotherapy that stands to revolutionize CAR T-cell therapy development and administration. Unlike existing methods that involve extracting, laboratory-manipulating, and reinfusing a patient’s T cells—a multistep, time-consuming, and costly processing vivo CAR T-cell therapy allows for direct genetic modification of T cells inside the patient’s body.
This is done by utilizing highly advanced delivery systems, e.g., viral vectors or nanoparticles, to deliver genetic material encoding CARs that enable T cells to promptly recognize and target cancer cells. These CARs are artificial receptors that are capable of binding particular antigens present on tumor cells and activating T cells via incorporated signaling domains, leading to proliferation and killing of tumor cells.
Developing over several generations, CAR constructs today comprise co-stimulatory and immunomodulatory components for improving efficacy, persistence, and safety. In vivo CAR T-cell therapy has the potential to overcome some of the major limitations of conventional ex vivo approaches by simplifying the process, decreasing costs, and shortening treatment timeframes to make it more accessible to patients globally.
Its chief uses are for hematological malignancies such as B-cell leukemia and lymphoma, where CAR T-cell treatment has already seen extensive success, but research continues to expand its applications to solid tumors and non-malignant conditions such as autoimmune diseases. The capacity to systemically or locally administer CAR genes to T cells creates new avenues for targeted and personalized therapies in a broad array of indications, placing in vivo CAR T-cell therapy as a revolutionary step in the evolution of immunotherapy.
List of Prominent Players in the In vivo CAR T-cell Market:
• Interius BioTherapeutics
• Capstan Therapeutics
• Esobiotec (AstraZeneca)
• Poseida Therapeutics
• Umoja Biopharma
• ORNA Therapeutics
• Vyriad (in collaboration with Novartis)
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04
In vivo CAR T-cell Market Report Scope:
Report Attribute Specifications
Market Size Value In 2024 USD XX Mn
Market Size Value In 2034 USD XX Mn
Growth rate CAGR CAGR of XX% from 2025 to 2034
Quantitative units Representation of revenue in US$ Mn, and CAGR from 2025 to 2034
Historic Year 2021 to 2024
Forecast Year 2025-2034
Report coverage The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends
Segments covered By Delivery Systems, Targets
Regional scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia
Market Dynamics:
Drivers-
The in vivo CAR T-cell market is propelled by its capacity to manufacture CAR T cells in situ, within the patient’s body, in hours rather than weeks, and avoid complex manufacturing. This streamlines logistics, lowers costs, and increases access outside of specialized centers. Emerging technology in delivery systems such as lentiviral vectors and lipid nanoparticles improves precision and safety.
The increasing cancer burden—almost 20 million new cases and 9.7 million deaths worldwide in 2022, including high-incidence forms such as breast, lung, colorectal, prostate, and hematologic malignancies—drives the need for more rapid, more accessible treatments, as research into solid tumors and non-oncology uses continues to increase market opportunity.
Challenges:
The in vivo CAR T-cell market faces key challenges including precise gene delivery to T cells, as off-target transduction can compromise safety and efficacy. Although attempting to lower costs, mass production of viral vectors or nanoparticles is still costly and sophisticated.
Moreover, safety risk management such as cytokine release syndrome, neurotoxicity, and off-target immune responses calls for sophisticated vector design and dosing regimens to deliver effective and safe therapy.
Regional Trends:
North America dominates the in vivo CAR T-cell market because of its modern R&D infrastructure, and the U.S. has state-of-the-art facilities with pivotal collaborations like Vyriad and Novartis’s collaboration. There is also a high incidence of hematological cancers such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), and an estimated thousands of new leukemia cases in 2024 are fueling demand for adequate therapy.
Its strong healthcare system—boasting more than 6,093 hospitals—facilitates broad clinical uptake. Key players such as Novartis, Kite Pharma, Bristol Myers Squibb, and Johnson & Johnson establish the market with several CAR T-cell products. Moreover, the U.S. leads worldwide clinical trial activity in CAR T-cell therapies, driving innovation and growing the therapeutic pipeline.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2999
Recent Developments:
• In Jan 2025, Interius BioTherapeutics received EU clearance to expand its INVISE Phase 1 trial—the first in vivo CAR gene therapy study approved in Europe. The trial evaluates INT2104, which generates CAR-T and CAR-NK cells in vivo to target CD20+ B-cell malignancies, marking a key step in advancing in vivo immunotherapies globally.
• In March 2025, AstraZeneca acquired EsoBiotec to gain its ENaBL platform, which enables in vivo cell therapies via simple IV injection in minutes, bypassing traditional, weeks-long processes. The move strengthens AstraZeneca’s position in next-gen cancer and immune disease treatments.
Segmentation of Trusted Platform Module Market-
By Delivery Systems:
• Lipid Nanoparticles (LNPs)
• Viral Vectors
• Oncolytic Viruses
By Targets:
• Hematological Cancers
• Solid Tumors
• Non-Oncology
By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/in-vivo-car-t-cell-market/2999
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com
Insight Ace Analytics
Diana D’souza
+1 551 226 6109
diana.dsouza@insightaceanalytics.com
Source: EmailWire.Com
Source link
